Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02621593 · ClinicalTrials.gov registry record · NA
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
A NA study of Dry Eye Syndromes, sponsored by Lumenis Be.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT02621593: Completed NA study of Dry Eye Syndromes, sponsored by Lumenis Be.
NCT02621593 is a NA study of Dry Eye Syndromes that has completed, run by Lumenis Be. The registered enrollment target is 44 participants, below the 412-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02621593, a NA study of Dry Eye Syndromes, has completed, sponsored by Lumenis Be.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to pre-treatment.
Primary Outcome
The number of seconds that elapse between the last blink of the eye to the appearance of the first dry spot in the tear film
Conditions Studied
Interventions
- DEVICE M22-IPL
Study Locations (2)
California
- Gaster Eye Center - Beverly Hills
Texas
- Dell Laser Consultants - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-01 |
| Phase | NA |
What the finished NCT02621593 record still lists
NCT02621593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 412-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 1 intervention - of which M22-IPL is the first listed.
NCT02621593 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT02621593 about?
NCT02621593 is a clinical study titled "Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD". The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to pre-treatment.
What is the current status of trial NCT02621593?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2015-10. Estimated completion is 2017-01.
What conditions does trial NCT02621593 study?
This clinical trial studies the following conditions: Dry Eye Syndromes.
What interventions are being tested in trial NCT02621593?
The interventions under investigation include: M22-IPL (DEVICE).
Who is sponsoring clinical trial NCT02621593?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02621593 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02621593's enrollment target sits among peer trials
44 13th of 17 higher than 5 of 17 other Dry Eye Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
-
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
COMPLETED · NA
-
TrueTear in Sjogren's Disease Patients
COMPLETED · NA
-
Corneal Epithelial Stem Cells and Dry Eye Disease
COMPLETED · NA
-
ACCURATE Study for Subjects With Dry Eyes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia